Chart Of The Day: J&J's One Shot Vaccine Could Propel Stock To New Records

 | Mar 02, 2021 09:43

According to Dr. Muriel Jean-Jacques, assistant professor of medicine at Northwestern University, Johnson & Johnson’s newly approved vaccine has two game-changing qualities.

It's one and done, so unlike the already available coronavirus inoculations from Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) there's no need for a second, follow-up shot. As well, in contrast to the other two vaccines, JNJ's version doesn't require specialized refrigeration such as the extreme freezers needed to store the earlier vaccines. Johnson & Johnson's (NYSE:JNJ) inoculation needs regular refrigeration only, enabling it to be delivered and administered in remote as well as urban locations around the world.   

Those factors together should be enough to enhance the company's fundamentals. The drugmaker says it's on track to deliver 4 million doses this week with an additional 100 million delivered worldwide by June.

But there are additional reasons the JNJ vaccine could be a booster rocket for the company's shares. It was also found to be effective against variants, such as the South African strain, with a 64% efficacy in preventing moderate to severe diseases. The inoculation has proven to be 85% efficient against severe illness and 100% effective in preventing death. Additional studies demonstrated a 72% efficacy rate at preventing moderate to severe disease.

It also happens that the vaccine’s delivery coincides with a technical setup indicating the stock is about to surge.